DPP IV inhibitor suppresses STZ-induced islets injury dependent on activation of the IGFR/Akt/mTOR signaling pathways by GLP-1 in monkeys

Biochemical and Biophysical Research Communications

Volumn 456, Issue 1, 2015, Pages 139-144

  Zhang, Yi ^a   Chen, Younan ^a   Cheng, Jingqiu ^a   Guo, Zhiguang ^b   Lu, Yanrong ^a   Tian, Bole ^a  

^a SICHUAN UNIVERSITY   (China)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

DPP IV inhibitors; Glucagon like peptide 1; IGF receptor; Islets injury

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; NVP AEW 541; PROTEIN KINASE B; SITAGLIPTIN; SOMATOMEDIN RECEPTOR; STREPTOZOCIN; WORTMANNIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; SOMATOMEDIN C RECEPTOR; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; IN VITRO STUDY; INSULIN BLOOD LEVEL; INSULIN RELEASE; NONHUMAN; PANCREAS ISLET; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RHESUS MONKEY; SIGNAL TRANSDUCTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; DRUG EFFECTS; INFLAMMATION; METABOLISM; OXIDATIVE STRESS;

ANIMALS; APOPTOSIS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; INFLAMMATION; INSULIN; ISLETS OF LANGERHANS; MACACA MULATTA; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; STREPTOZOCIN; TOR SERINE-THREONINE KINASES;

EID: 84919620889     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.11.048     Document Type: Article

References (17)

1. E. Rask, T. Olsson, S. Söderberg, O. Johnson, J. Seckl, J.J. Holst, B. Ahrén Northern Sweden Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA) Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men Diabetes Care 24 9 2001 1640 1645
2. Y. Li, T. Hansotia, B. Yusta, F. Ris, P.A. Halban, and D.J. Drucker Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis J. Biol. Chem. 278 1 2003 471 478 (Epub 2002 October 29)
3. A. Consoli, and R. DiBiagio Protective effects of glucagon-like peptide-1 on beta-cells: preclinical and clinical data G. Ital. Cardiol. (Rome) 12 12 Suppl. 2 2011 5 9 http://dx.doi.org/10.1714/985.10684
4. L. Jin, S.W. Lim, K.C. Doh, S.G. Piao, J. Jin, S.B. Heo, B.H. Chung, and C.W. Yang Dipeptidyl peptidase IV inhibitor MK-0626 attenuates pancreatic islet injury in tacrolimus-induced diabetic rats PLoS ONE 9 6 2014 e100798 10.1371/journal.pone.0100798 (eCollection)
5. R. Agrawal, P. Jain, and S.N. Dikshit Linagliptin: a novel methylxanthine based approved dipeptidyl peptidase-4 inhibitor Curr. Drug Targets 13 7 2012 970 983
6. A. Vetere, A. Choudhary, S.M. Burns, and B.K. Wagner Targeting the pancreatic β-cell to treat diabetes Nat. Rev. Drug Discov. 13 4 2014 278 289
7. S.D. Edmondson, A. Mastracchio, R.J. Mathvink, J. He, B. Harper, Y.J. Park, M. Beconi, J. Di Salvo, G.J. Eiermann, H. He, B. Leiting, J.F. Leone, D.A. Levorse, K. Lyons, R.A. Patel, S.B. Patel, A. Petrov, G. Scapin, J. Shang, R.S. Roy, A. Smith, J.K. Wu, S. Xu, B. Zhu, N.A. Thornberry, and A.E. Weber (2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes J. Med. Chem. 49 12 2006 3614 3627
8. C.M. Shih, Y.H. Chen, Y.W. Lin, N.W. Tsao, S.C. Wu, Y.T. Kao, K.H. Chiang, C.Y. Li, N.C. Chang, C.Y. Lin, C.Y. Huang, and F.Y. Lin MK-0626, a dipeptidyl peptidase-4 inhibitor, improves neovascularization by increasing both the number of circulating endothelial progenitor cells and endothelial nitric oxide synthetase expression Curr. Med. Chem. 21 17 2014 2012 2022
9. S. He, D. Wang, and L. Wei Practical and critical instruction for nonhuman primate diabetic models Transplant. Proc. 45 5 2013 1856 1865
10. S. He, D. Wang, Y. Lu, Y. Chen, X. Jin, C. Wang, J. Zhao, Y. Ren, L. Wang, H. Li, and J. Cheng Increasing glucagon secretion could antagonize the action of exogenous insulin for glycemic control in streptozocin-induced diabetic rhesus monkeys Exp. Biol. Med. (Maywood) 238 4 2013 385 391
11. H.D. Yuan, and S.H. Chung Protective effects of fermented ginseng on streptozotocin-induced pancreatic beta-cell damage through inhibition of NF-kappaB Int. J. Mol. Med. 25 1 2010 53 58
12. D.A. Stoffers, T.J. Kieffer, M.A. Hussain, D.J. Drucker, S. Bonner-Weir, J.F. Habener, and J.M. Egan Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas Diabetes 49 5 2000 741 748
13. G. Xu, D.A. Stoffers, J.F. Habener, and S. Bonner-Weir Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats Diabetes 48 12 1999 2270 2276
14. B.A. O'Brien, B.V. Harmon, D.P. Cameron, and D.J. Allan Beta-cell apoptosis is responsible for the development of IDDM in the multiple low-dose streptozotocin model J. Pathol. 178 2 1996 176 181
15. M. Cornu, and B. Thorens GLP-1 protects β-cells against apoptosis by enhancing the activity of an IGF-2/IGF1-receptor autocrine loop Islets 1 3 2009 280 282
16. B. Thorens Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1 Proc. Natl. Acad. Sci. U.S.A. 89 1992 8641 8645
17. T.B. Usdin, E. Mezey, D.C. Button, M.J. Brownstein, and T.I. Bonner Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain Endocrinology 133 1993 2861 2870